Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Rhea-AI Summary

Psyence Biomedical (Nasdaq: PBM) announced that the SEC has declared effective its registration statement for a $25 million equity line of credit (ELOC) with White Lion Capital, This 24-month arrangement allows Psyence Biomed to sell up to $25 million in shares to White Lion, subject to certain conditions.

Dr. Neil Maresky, CEO of Psyence Biomed, stated that this funding source will support the company's preparation for a Phase IIb clinical trial of nature-derived, non-synthetic psilocybin as a potential treatment for Adjustment Disorder in Palliative Care. The company also plans to advance other long-term growth initiatives.

Positive

• SEC declared effective the $25 million equity line of credit registration statement
• Potential funding source secured for upcoming Phase IIb clinical trial
• 24-month arrangement provides financial flexibility

Negative

• Potential dilution of existing shareholders due to share issuance
• Funding is subject to certain conditions, which may limit access to capital

Insights

Financial Analyst

The SEC's approval of Psyence Biomed's $25 million equity line of credit (ELOC) with White Lion Capital is a significant financial development. This 24-month arrangement provides the company with a flexible funding source, important for its upcoming Phase IIb clinical trial and long-term growth initiatives. However, investors should note that this is not guaranteed capital. The ELOC allows Psyence to sell up to $25 million in shares, subject to conditions. This could lead to potential dilution for existing shareholders if utilized extensively. The effectiveness of this funding strategy will largely depend on the company's ability to meet the undisclosed conditions and the market's reception to potential share issuances.

Medical Research Analyst

Psyence Biomed's focus on nature-derived, non-synthetic psilocybin for Adjustment Disorder in Palliative Care is intriguing. The progression to a Phase IIb trial suggests promising earlier results, but investors should remain cautious. The palliative care context is a unique niche that could potentially face less regulatory hurdles compared to broader applications of psychedelics. However, the effectiveness and safety profile of their specific formulation in this sensitive patient population will be crucial. The success of this trial could position Psyence as a pioneer in this emerging field, but it's important to note that psychedelic research is still in its early stages, with potential regulatory and public perception challenges ahead.

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that the registration statement pertaining to its previously announced $25 million equity line of credit (the “ELOC”) with White Lion Capital, LLC, (“White Lion”) on Form F-1 has been declared effective by the U.S. Securities and Exchange Commission (SEC) on August 28, 2024. As previously disclosed, this 24-month arrangement allows Psyence Biomed to sell up to $25 million in shares to White Lion, subject to certain conditions.

“With the effectiveness of this registration statement, we now have an important source of potential funding through White Lion as we prepare to initiate our Phase IIb clinical trial of nature derived, non-synthetic psilocybin as a potential treatment for Adjustment Disorder in the Palliative Care context, while also advancing other key long-term growth initiatives,” said Dr. Neil Maresky, Chief Executive Officer of Psyence Biomed. “We are grateful to White Lion for their support of our vision and our team, and we look forward to a long and mutually successful partnership.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Psyence Biomed

Psyence Biomedical Ltd. (Nasdaq: PBM) is the world’s first life science biotechnology company focused on the development of botanical (nature-derived, or non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. The Company is initially focused on mental health disorders in the context of Palliative Care.

Learn more at www.psyencebiomed.com and on LinkedIn.

Contact Information

Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708

Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com

Forward Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning.

Forward-looking statements in this communication include statements regarding the commencement of the clinical trial referred to in this news release, the safety and effectiveness of psilocybin as a treatment option for adjustment disorder within the context of Palliative Care, and the Company exercising its discretion to utilise the ELOC. These forward-looking statements are based on a number of assumptions, including the assumption that the anticipated shipment of the drug candidate, PEX010, will be successfully delivered to Australia, Psyence Australia Pty Ltd. (“Psyence Australia”), the Company’s Australian subsidiary, will receive all such regulatory and other approvals as may be required to implement the clinical trial, that patient recruitment will be successful in accordance with the expected timelines, and that the Company will satisfy all of the equity conditions and other conditions contained in the Purchase agreement to utilise the ELOC.

There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among others: (i) the ability of iNGENū to execute its obligations in respect of the clinical trial; (ii) changes in applicable laws which may impact the clinical trial and/or the conducting thereof; (iii) Psyence Australia’s ability to achieve successful clinical results; (iv) Psyence Biomed’s ability to obtain regulatory approval for its product candidates, and any related restrictions or limitations of any approved products; (v) Psyence Biomed’s ability to obtain licensing of third-party intellectual property rights and supply of raw materials for future discovery and development of its product candidates; (vi) the ability of Psyence Biomed to maintain the listing of its common shares and warrants on Nasdaq; and (vii) volatility in the price of the securities of Psyence Biomed due to a variety of factors, including changes in the competitive and highly regulated industries in which Psyence Biomed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence Biomed’s business and changes in Psyence Biomed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of the Registration Statement on Form F-1, filed by the Company with the SEC on August 19, 2024 and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such information. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, the Company does not intend to update these forward-looking statements.

The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.

FAQ

What is the value of Psyence Biomed's (PBM) equity line of credit with White Lion Capital?

Psyence Biomed (PBM) has secured a $25 million equity line of credit with White Lion Capital,

What clinical trial is Psyence Biomed (PBM) preparing to initiate?

Psyence Biomed (PBM) is preparing to initiate a Phase IIb clinical trial of nature-derived, non-synthetic psilocybin as a potential treatment for Adjustment Disorder in Palliative Care.

When was Psyence Biomed's (PBM) registration statement declared effective by the SEC?

Psyence Biomed's (PBM) registration statement was declared effective by the SEC on August 28, 2024.

What is the duration of Psyence Biomed's (PBM) equity line of credit arrangement?

Psyence Biomed's (PBM) equity line of credit arrangement with White Lion Capital has a duration of 24 months.